Drug Profile
Leflunomide - sanofi-aventis
Alternative Names: Arava; HWA 486; SU 101Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Pfizer
- Class Antineoplastics; Disease-modifying antirheumatics; Isoxazoles; Small molecules
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Dihydropteroate synthase inhibitors; Epidermal growth factor receptor antagonists; Immunosuppressants; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Psoriatic arthritis; Rheumatoid arthritis
- Discontinued Anaplastic astrocytoma; Autoimmune disorders; Cytomegalovirus infections; Glioblastoma; Graft-versus-host disease; Hypersensitivity; Immune-mediated uveitis; Multiple sclerosis; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Psoriasis; Systemic lupus erythematosus; Transplant rejection
Most Recent Events
- 03 Dec 2018 Chang Zheng-Cinkate Pharmaceutical Corporation terminates a phase II trial for the prevention of kidney Transplant rejection in the USA due to lack of recruitment (PO) (NCT01620268)
- 01 Oct 2015 Generic equivalent available in USA for Rheumatoid arthritis
- 26 Sep 2013 added SU101 to synonyms